Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Angiology. 2012 Aug;63(6):429-34. doi: 10.1177/0003319712436755. Epub 2012 Feb 17.
Plasminogen activator inhibitor 1 (PAI-1), the primary inhibitor of fibrinolysis and C-reactive protein (CRP), is a predictor of myocardial infarction. Both are upregulated by tumor necrosis factor-alpha (TNF-α) within the obese population. This pilot study tested the hypothesis that TNF-α blockade with pentoxifylline lowers PAI-1 and high-sensitivity CRP (hsCRP) in obese individuals. Twenty participants were treated with pentoxifylline for 8 weeks. A proportional odds model was used to compare the change in PAI-1 and CRP in the pentoxifylline and placebo groups. Plasminogen activator inhibitor 1, but not hsCRP levels, decreased over the 8-week period of the study (P = .025 and P = NS). There was significant dropout of participants due to drug tolerability. These findings suggest that these markers of cardiovascular risk are differentially regulated in obesity and that PAI-1 levels can be reduced by pentoxifylline in this population.
纤溶酶原激活物抑制剂 1（PAI-1）是纤维蛋白溶解的主要抑制剂和 C 反应蛋白（CRP），是心肌梗死的预测因子。在肥胖人群中，两者均受肿瘤坏死因子-α（TNF-α）的上调。这项初步研究检验了这样一个假设，即通过己酮可可碱阻断 TNF-α可降低肥胖个体的 PAI-1 和高敏 C 反应蛋白（hsCRP）。20 名参与者接受己酮可可碱治疗 8 周。采用比例优势模型比较己酮可可碱组和安慰剂组 PAI-1 和 CRP 的变化。研究期间，PAI-1 水平而非 hsCRP 水平在 8 周内下降（P =.025 和 P = NS）。由于药物耐受性，参与者大量脱落。这些发现表明，这些心血管风险标志物在肥胖中受到不同的调节，并且 PAI-1 水平可以通过己酮可可碱在该人群中降低。
